REG - Mast Energy Dvlpmts. - Further Funding Secured

Mast Energy DevelopmentsAnnouncement

03/11/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20221103:nRSC1462Fa&default-theme=true

RNS Number : 1462F  Mast Energy Developments PLC  03 November 2022

Mast Energy Developments PLC

(Incorporated in England and Wales)

(Registration Number: 12886458)

Share code on the LSE: MAST

ISIN: GB00BMBSCV12

("MED" or "the Company")

 

03 November 2022

 

Mast Energy Developments PLC ("MED" or "the Company")

 

 Further Funding Secured

 

Mast Energy Developments PLC, the UK-based multi-asset owner and operator in
the rapidly growing Reserve Power market is pleased to announce that it has
entered into arrangements in respect of the provision of a new loan facility
for up to £2.25 million (the "Loan Facility") with a total committed advance
of £475,000 (the "Committed Advance"), of which the first £300,000 is to be
received by the Company on the date of execution of the loan agreement (the
"Initial Advance"). The key terms of the Loan Facility are provided below.

 

The Committed Advance will predominantly be used to fast-track the development
of MED's current projects, most notably the most recent acquisitions, Hindlip
Lane and Stather Road (see RNS dated 5 October 2022).

 

Loan Facility

 

MED has been approached by various institutional investors and lenders which
were interested in providing MED with project development funding, in order
for MED to fast track the development of its projects to get to financial
close and into construction and production. The approaches received included
the same institutional investor led group ("Institutional Investor") with
which MED entered into a loan agreement recently to acquire its most recent
two new projects (see RNS dated 5 October 2022). After due and careful
consideration, MED decided to accept the Institutional Investor's funding
offer, which shows their continued belief and commitment in MED, its business
model and potential.

 

Key Terms:

·    New unsecured loan facility of up to £2.25 million with a commitment
period of three years led by an institutional investor (the "Institutional
Investor");

·    The Loan Facility may be drawn down in multiple instalments, subject
to the mutual agreement of the parties and the satisfaction of certain
customary conditions precedent;

·    The Initial Advance of £300,000 is to be paid to the Company on the
date of execution of the loan agreement, with the Company being able to
request from the Institutional Investor up to £175,000 in a single further
tranche (together with the Initial Advance, the "Committed Advance"), and any
further advances to be agreed between the Institutional Investor and the
Company at the relevant time;

·    The Company will pay a fixed annual interest coupon to the
Institutional Investor on a quarterly basis calculated as 10% of the value of
each principal advance of the Loan Facility;

·    Each principal advance of the Loan Facility will have a maturity date
of 18 months (the "Term") from the date of advance (the "Maturity Date") with
repayments of any outstanding balances repaid in cash on the Maturity Date;

·    It is MED's intention that the principal is to be repaid in cash from
existing revenue streams, however MED and the Institutional Investor may agree
that the Company satisfies any payment of the amounts due under the Loan
Facility agreement by the issue of ordinary shares in the capital of the
Company ("Ordinary Shares");

·    If such settlement is agreed by the parties, the value of Ordinary
Shares the Institutional Investor will receive being settled in lieu of
repayment of the debt will be the lowest of the:

o Fixed Premium Placing Price - being at a 30% premium to the average daily
VWAP for each of the five consecutive trading days preceding the drawdown date
of each advance of the Loan Facility, or

o Variable Placing Price - being at 90% of the average of the lowest daily
VWAP of the 10 daily VWAPs preceding each relevant conversion notice.

·    The Company will comply with any requirements under the Prospectus
Regulation Rules with regard to share capital headroom, including if required
issuing a prospectus;

·    In consideration for providing the Loan Facility the Institutional
Investor shall receive warrants equal to 40% of each drawdown advance divided
by the average of the daily VWAP for each of the five consecutive trading days
immediately prior to the applicable drawdown date (the "Reference Price"),
with a 36-month term to expiry from the date of issuance;

·    The warrants are exercisable at a subscription price being equal to a
30% premium of the then prevailing Reference Price;

·    All warrants exercised will be a cash injection into the Company if
exercised or set-off against outstanding principal of the Loan Facility, to
reduce cash repayment balances; and

·    With regards to the Committed Advance, the Institutional Investor
will receive 4,686,868 warrants, and such warrants will be granted on the
earlier date that the Company has an approved prospectus or when its share
capital headroom refreshes annually under its listing rules.

 

Pieter Krügel, MED CEO, commented: "Pursuant to our development process, we
are pleased to have secured additional funding by way of a further loan with
competitive commercial terms. The loan and cash injection will assist MED to
fast-track the development of its current portfolio of projects under
development in order to get each project into production as soon as possible,
and to increase MED's participation in and benefit of the current and ongoing
unprecedent energy market prices. We are also continually looking to further
grow the portfolio to get to the first 100 MW and then the ultimate strategic
intent of a 300 MW portfolio.

We look forward to providing the market with further updates in due course as
we progress."

ENDS

This announcement contains inside information for the purposes of the UK
version of the Market Abuse Regulation (EU No. 596/2014) as it forms part of
United Kingdom domestic law by virtue of the European Union (Withdrawal) Act
2018 ("UK MAR"). Upon the publication of this announcement, this inside
information is now considered to be in the public domain.

 

For further information please visit www.med.energy (http://www.med.energy) or
contact:

 

  Pieter Krügel                          info@med.energy                                                       Mast Energy Developments Plc  CEO
  Jonathan Critchley & Keith Swann       +44 (0)20 3869 6080                                                   Clear Capital Markets         Joint Broker
  Zainab Slemang van Rijmenant           zainab@lifacommunications.com (mailto:zainab@lifacommunications.com)  Lifa Communications           Investor and Media

                                                                                                                                             Relations Advisor

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCFSUEDEEESESF